Description
- Polivy (polatuzumab Vedotin-piiq) is a CD79b-directed antibody and microtubule inhibitor conjugate used: in combination with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for the treatment of adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index score of 2 or greater.
- in combination with bendamustine and a rituximab product for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), NOS, after at least two prior therapies.
Posology & Administration: Patients with Previously Untreated DLBCL, NOS, or HGBL: The prescribed dose of Polivy injection is 1.8 mg/kg, given via intravenous infusion once every 21 days for a total of 6 cycles. It is combined with a rituximab product, cyclophosphamide, doxorubicin, and prednisone. On Day 1, Polivy, cyclophosphamide, doxorubicin, and the rituximab product are administered in any sequence following the administration of prednisone. Prednisone is given from Day 1 to Day 5 of each cycle.
Patients with Relapsed or Refractory DLBCL, NOS: The prescribed regimen for Polivy entails administering 1.8 mg/kg intravenously every 21 days for six cycles in conjunction with bendamustine and a rituximab product. On Day 1 of each cycle, Polivy, bendamustine, and the rituximab product should be administered in any sequence. Bendamustine should be given at a dose of 90 mg/m2/day on Days 1 and 2 when used with Polivy and a rituximab product. Additionally, the recommended dose of the rituximab product is 375 mg/m2 intravenously on Day 1 of every cycle.
If a scheduled dose is missed, administer it promptly and adjust the dosing schedule to maintain a 21-day interval between doses.